PMID- 29341502
OWN - NLM
STAT- MEDLINE
DCOM- 20180821
LR  - 20180821
IS  - 1757-5672 (Electronic)
IS  - 1757-5664 (Linking)
VI  - 10
IP  - 1
DP  - 2018 Jan
TI  - Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial 
      cystitis (IC).
PG  - 3-11
LID - 10.1111/luts.12214 [doi]
AB  - Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic symptom 
      complex that may cause bothersome storage symptoms and pain or discomfort of the 
      bladder, adversely affecting a patient's quality of life. The etiology of IC/BPS 
      remains unclear, and its cause may be multifactorial. Diagnosis of IC/BPS is 
      based on clinical features, and the possibility of other conditions must be ruled 
      out first. Although no definitive treatment is currently available for IC/BPS, 
      various intravesical therapies are used for IC/BPS, including heparin, hyaluronic 
      acid, chondroitin sulfate, pentosan polysulfate, dimethylsulfoxide, liposomes, 
      and botulinum onabotulinumtoxinA (BoNT-A). This review summarizes the 
      intravesical therapy for IC/BPS and discusses recent advances in the instillation 
      of liposomal-mediated BoNT-A and other newly developed intravesical therapies.
CI  - (c) 2018 John Wiley & Sons Australia, Ltd.
FAU - Meng, En
AU  - Meng E
AD  - Department of Urology, Tri-Service General Hospital, National Defense Medical 
      Center, Taipei, Taiwan.
FAU - Hsu, Yu-Chao
AU  - Hsu YC
AD  - Department of Urology, Linko Chang Gung Memorial Hospital, Taipei, Taiwan.
AD  - College of Medicine, Chang Gung University, Taipei, Taiwan.
FAU - Chuang, Yao-Chi
AU  - Chuang YC
AUID- ORCID: 0000-0002-1468-3792
AD  - Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung 
      University College of Medicine, Kaohsiung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Low Urin Tract Symptoms
JT  - Lower urinary tract symptoms
JID - 101506777
RN  - 0 (Acetylcholine Release Inhibitors)
RN  - 0 (Anesthetics, Local)
RN  - 0 (Anticoagulants)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Liposomes)
RN  - 0 (Urological Agents)
RN  - 37300-21-3 (Pentosan Sulfuric Polyester)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - 9005-49-6 (Heparin)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - 98PI200987 (Lidocaine)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - EC 3.4.24.69 (incobotulinumtoxinA)
RN  - YOW8V9698H (Dimethyl Sulfoxide)
SB  - IM
MH  - Acetylcholine Release Inhibitors/*administration & dosage
MH  - Administration, Intravesical
MH  - Anesthetics, Local/administration & dosage
MH  - Anticoagulants/administration & dosage
MH  - Botulinum Toxins, Type A/*administration & dosage
MH  - Chondroitin Sulfates/administration & dosage
MH  - Cystitis, Interstitial/*drug therapy/epidemiology
MH  - Dimethyl Sulfoxide/administration & dosage
MH  - Free Radical Scavengers/administration & dosage
MH  - Heparin/administration & dosage
MH  - Humans
MH  - Hyaluronic Acid/administration & dosage
MH  - Lidocaine/administration & dosage
MH  - Liposomes
MH  - Pentosan Sulfuric Polyester/administration & dosage
MH  - Urological Agents/*administration & dosage
OTO - NOTNLM
OT  - bladder pain syndrome
OT  - interstitial cystitis
OT  - intravesical therapy
EDAT- 2018/01/18 06:00
MHDA- 2018/08/22 06:00
CRDT- 2018/01/18 06:00
PHST- 2017/10/17 00:00 [received]
PHST- 2017/11/19 00:00 [revised]
PHST- 2017/12/01 00:00 [accepted]
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/08/22 06:00 [medline]
AID - 10.1111/luts.12214 [doi]
PST - ppublish
SO  - Low Urin Tract Symptoms. 2018 Jan;10(1):3-11. doi: 10.1111/luts.12214.